HUTCHMED reports preclinical antitumor activity for HMPL-A830
HCM•
HCM•HUTCHMED said HMPL-A830 produced more durable tumor regressions than KRAS G12C inhibitors in mouse models. A global Phase Ia trial is ongoing, and a GSK subsidiary has rights to develop and commercialize the therapy outside specified Asian territories.
HUTCHMED highlighted results for HMPL-A830 presented at a cancer therapeutics conference in Barcelona on Nov. 18, 2026. In mouse models, the EGFR-targeted KRAS therapy produced more durable tumor regressions than KRAS G12C inhibitors and outperformed several comparator treatments.
An ongoing global Phase Ia trial is evaluating HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors. Under a September 2026 agreement, a GSK subsidiary received development and commercialization rights outside Mainland China, Hong Kong, Macau and Taiwan; HUTCHMED retains responsibility for global Phase I development.